AR128985A1 - Forma cristalina de lanifibranor - Google Patents
Forma cristalina de lanifibranorInfo
- Publication number
- AR128985A1 AR128985A1 ARP230100832A ARP230100832A AR128985A1 AR 128985 A1 AR128985 A1 AR 128985A1 AR P230100832 A ARP230100832 A AR P230100832A AR P230100832 A ARP230100832 A AR P230100832A AR 128985 A1 AR128985 A1 AR 128985A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline form
- lanifibranor
- diffraction pattern
- ray
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305456 | 2022-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128985A1 true AR128985A1 (es) | 2024-07-03 |
Family
ID=81326293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100832A AR128985A1 (es) | 2022-04-05 | 2023-04-04 | Forma cristalina de lanifibranor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250243192A1 (https=) |
| EP (1) | EP4504725A1 (https=) |
| JP (1) | JP2025511847A (https=) |
| KR (1) | KR20250002337A (https=) |
| CN (1) | CN119301120A (https=) |
| AR (1) | AR128985A1 (https=) |
| AU (1) | AU2023250118A1 (https=) |
| CA (1) | CA3247273A1 (https=) |
| IL (1) | IL316075A (https=) |
| MX (1) | MX2024012348A (https=) |
| PY (1) | PY2324870A (https=) |
| TW (1) | TW202404966A (https=) |
| UY (1) | UY40216A (https=) |
| WO (1) | WO2023194339A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240047402A (ko) * | 2021-08-12 | 2024-04-12 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 라니피브라노르의 결정형, 이의 제조 방법 및 이의 용도 |
| CN120857930A (zh) | 2023-01-19 | 2025-10-28 | 伊文蒂瓦公司 | 拉尼兰诺制剂 |
| KR20260020956A (ko) | 2023-06-05 | 2026-02-12 | 엥방티바 | 간 질환을 가진 환자의 내장 혈관 확장증의 치료에 사용하기 위한 라니피브라노르 |
| WO2025061927A1 (en) * | 2023-09-22 | 2025-03-27 | Inventiva | Method of making lanifibranor |
| WO2025132989A1 (en) | 2023-12-21 | 2025-06-26 | Inventiva | Combination therapy for the prevention and/or the treatment of a liver disease |
| WO2025132955A1 (en) | 2023-12-21 | 2025-06-26 | Inventiva | Combination therapy for the prevention and/or the treatment of a liver disease |
| TW202543596A (zh) | 2024-03-15 | 2025-11-16 | 法商因文帝華公司 | 預防接受過氧化物酶體增生劑活化受體（ppar）促效劑治療患者之血液病症 |
| WO2025191292A1 (en) | 2024-03-15 | 2025-09-18 | Inventiva | Methods and monitoring of treatment with lanifibranor |
| WO2025238200A1 (en) | 2024-05-17 | 2025-11-20 | Inventiva | Treatment of a liver disease in patients with hepatic impairment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2890071B1 (fr) | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| WO2022122014A1 (zh) | 2020-12-11 | 2022-06-16 | 苏州科睿思制药有限公司 | Lanifibranor的晶型及其制备方法和用途 |
| WO2022143479A1 (zh) | 2020-12-29 | 2022-07-07 | 广东东阳光药业有限公司 | 一种化合物的固体形式及其制备方法和用途 |
| WO2022261410A1 (en) | 2021-06-10 | 2022-12-15 | Teva Pharmaceuticals International Gmbh | Solid state forms of lanifibranor and process for preparation thereof |
| CN115466252A (zh) | 2021-06-11 | 2022-12-13 | 上海希迈医药科技有限公司 | 一种Lanifibranor的晶型及其制备方法 |
| KR20240047402A (ko) | 2021-08-12 | 2024-04-12 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 라니피브라노르의 결정형, 이의 제조 방법 및 이의 용도 |
-
2023
- 2023-03-31 TW TW112112450A patent/TW202404966A/zh unknown
- 2023-04-04 WO PCT/EP2023/058743 patent/WO2023194339A1/en not_active Ceased
- 2023-04-04 PY PY202302324870A patent/PY2324870A/es unknown
- 2023-04-04 IL IL316075A patent/IL316075A/en unknown
- 2023-04-04 JP JP2024559386A patent/JP2025511847A/ja active Pending
- 2023-04-04 CA CA3247273A patent/CA3247273A1/en active Pending
- 2023-04-04 CN CN202380042246.2A patent/CN119301120A/zh active Pending
- 2023-04-04 AR ARP230100832A patent/AR128985A1/es unknown
- 2023-04-04 EP EP23717474.3A patent/EP4504725A1/en active Pending
- 2023-04-04 AU AU2023250118A patent/AU2023250118A1/en active Pending
- 2023-04-04 US US18/854,287 patent/US20250243192A1/en active Pending
- 2023-04-04 KR KR1020247036771A patent/KR20250002337A/ko active Pending
- 2023-04-10 UY UY0001040216A patent/UY40216A/es unknown
-
2024
- 2024-10-04 MX MX2024012348A patent/MX2024012348A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023250118A1 (en) | 2024-10-17 |
| JP2025511847A (ja) | 2025-04-16 |
| KR20250002337A (ko) | 2025-01-07 |
| WO2023194339A1 (en) | 2023-10-12 |
| TW202404966A (zh) | 2024-02-01 |
| EP4504725A1 (en) | 2025-02-12 |
| CN119301120A (zh) | 2025-01-10 |
| MX2024012348A (es) | 2024-11-08 |
| IL316075A (en) | 2024-12-01 |
| PY2324870A (es) | 2023-10-27 |
| CA3247273A1 (en) | 2023-10-12 |
| UY40216A (es) | 2023-10-31 |
| US20250243192A1 (en) | 2025-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128985A1 (es) | Forma cristalina de lanifibranor | |
| AR124911A1 (es) | Sólidos cristalinos del inhibidor mek n-((r)-2,3-dihidroxipropoxi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y usos de los mismos | |
| CO2021016594A2 (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
| AR034124A1 (es) | Forma cristalina alfa de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| UY29277A1 (es) | Derivados de benzamidas (4(4-(1-isopropil-2-metil-1h-imidazol-5-il)-pirimidin-2-il)amino)sustitudas, composiciones que los contienen, procedimiento de preparación y aplicaciones | |
| JP2012527481A5 (https=) | ||
| JP2011516483A5 (https=) | ||
| AR052948A1 (es) | DERIVADOS DE ACETILENIL-PIRAZOLO-PIRIMIDINA COMO ANTAGONISTAS DE MGLUR2, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES DEL SNC | |
| RU2009122241A (ru) | Твердые формы рацемического илапразола | |
| UY28695A1 (es) | Derivados de difenilazetidona | |
| PE20252755A1 (es) | Formas cristalinas de un inhibidor de ras | |
| JPH02503318A (ja) | 化合物 | |
| AU2013301156A1 (en) | Process for the preparation of pemetrexed and lysin salt thereof | |
| AR071311A1 (es) | Compuesto de maleato de orvepitant cristalino anhidro (forma 1), composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento util para el tratamiento o profilaxis de enfermedades del snc | |
| SG11201900754XA (en) | Catalyst for production of methacrylic acid, method of producing the same, method of producing methacrylic acid, and method of producing methacrylic acid ester | |
| CO6270318A2 (es) | Acido 4-[4-(2adamantilcarbomoil)-5-tert-butilpirazol -1-il]benzoico-465 | |
| PE20251400A1 (es) | Derivados de co-cristales de 4-[4-[3-cloro-4-[1- (2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con acido galico y amida nicotinica | |
| PE20231071A1 (es) | Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1- il)fenil]-6-oxo-1,6-dihidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15- tetraazatriciclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona | |
| BR112021024039A2 (pt) | Sínteses de furanos substituídos | |
| Ouédraogo et al. | 2-Oxo-2H-chromen-7-yl 4-tert-butylbenzoate | |
| ES2527354T3 (es) | Anhidrato de 8-cloro-3-pentil-3,7-dihidro-1H-purina-2,6-diona 2-amino-2-(hidroximetil)-1,3-propanodiol para el tratamiento de enfermedades | |
| Adamovich et al. | Biologically active protic (2-hydroxyethyl) ammonium ionic liquids. Liquid aspirin | |
| AR040692A1 (es) | Polimorfo del dodecahidrociclopenta(a)fenantrenil ester del acido tiofenilcarboxilico |